Advicenne

Rare disease has become a real area of focus and growth for drug development. According to Citeline’s Pharma R&D Annual Review 2023 , more than 30% of all drug development is targeted against rar

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Adaptimmune, TCR² Combine Forces, Incre

The European Commission has approved Advicenne ’s Sibnayal for the orphan disease distal renal tubular acidosis (dRTA). The approval came after the company voluntarily withdrew the orphan drug design

The European Medicines Agency has recommended that Enhertu and Retsevmo should be approved in the EU sooner than they normally would because the drugs, made by Daiichi Sankyo Co / AstraZeneca and E